论文部分内容阅读
目的检测难治性ITP患者内源性血清白介素-11(IL-11)的分泌水平。观察重组人白介素-11单药治疗难治性特发性血小板减少性紫癜(ITP)的临床效果。方法选血小板在2万以下的21例难治性ITP患者,应用ELISA法测定患者治疗前血清IL-11水平,以25例体检健康人为正常对照,比较治疗前内源性IL-11的分泌水平较正常人是否升高。用重组人IL-11单药治疗以上21例患者共14d,用法:50μg/kg,每天1次皮下注射,比较用药前后血小板计数是否存在差异。结果治疗前21例患者血清IL-11水平(246.0±133.5)pg/ml明显高于正常对照组(46.2±14.2)pg/ml(P﹤0.01)。21例患者用药前血小板计数平均值为(14.0±3.4)×109/L,用药后平均值为(58.9±35.1)×109/L,治疗后的血小板较治疗前显著升高(P﹤0.01)。治疗后2个月血小板平均值为(46.5±29.5)×109/L,比用药前高,但较d14下降。结论治疗前内源性IL-11水平分泌增高。IL-11能有效提高难治性ITP患者的血小板水平。
Objective To detect the secretion of endogenous serum interleukin-11 (IL-11) in patients with refractory ITP. To observe the clinical effect of recombinant human interleukin-11 monotherapy in the treatment of refractory idiopathic thrombocytopenic purpura (ITP). Methods Twenty-one patients with refractory ITP with platelet count less than 20,000 were enrolled in this study. Serum IL-11 level before treatment was measured by ELISA. The level of endogenous IL-11 secretion was compared between 25 healthy volunteers before treatment Is it higher than normal? The above 21 patients treated with recombinant human IL-11 monotherapy for a total of 14 days, usage: 50μg / kg, 1 times daily subcutaneous injection, comparison of the platelet count before and after treatment for differences. Results The levels of IL-11 in the serum of 21 patients before treatment (246.0 ± 133.5 pg / ml) were significantly higher than those of the normal control group (46.2 ± 14.2 pg / ml) (P <0.01). The average value of platelet count before treatment was (14.0 ± 3.4) × 109 / L in 21 patients, and (58.9 ± 35.1) × 109 / L after treatment. The platelets after treatment were significantly higher than those before treatment (P <0.01) . The average platelet count at 2 months after treatment was (46.5 ± 29.5) × 109 / L, higher than before treatment, but lower than d14. Conclusion The secretion of endogenous IL-11 increased before treatment. IL-11 is effective in increasing platelet levels in patients with refractory ITP.